Royalty Pharma plc
RPRX
Rang in aandelen
#869
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aandeelprijs
$62.21
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$27.70B
Verandering (1 dag)
3.22%
Verandering (1 jaar)
65.98%
Land
US
Handel Royalty Pharma plc (RPRX)
Categorie
Healthcare
P/B-ratio voor Royalty Pharma plc (RPRX)
P/B-ratio op October 2026 TTM: 3.84
Volgens de meest recente financiële rapporten en aandelenkoers van Royalty Pharma plc is de huidige P/B-ratio (TTM) 3.84. Eind 2023 had het bedrijf een P/B-ratio van 1.93.
P/B-ratiohistoriek voor Royalty Pharma plc van 2015 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.84 | 134.29% |
| 2024 | 1.64 | -14.99% |
| 2023 | 1.93 | -37.36% |
| 2022 | 3.08 | 7.47% |
| 2021 | 2.86 | -29.02% |
| 2020 | 4.03 | 56.17% |
| 2019 | 2.58 | -26.49% |
| 2018 | 3.51 | -0.62% |
| 2017 | 3.53 | -41.85% |
| 2016 | 6.08 | 5.20% |
| 2015 | 5.78 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 351.64% |
US
|
|
| 2.4753 | -35.58% |
HK
|
